NuraLogix Showcases New Platform at ViVE, Allowing Continuous Health and Vital Sign Measurements During Telehealth Calls
Facial blood flow patterns unlock a wealth of health data during telehealth consultations
NuraLogix, a global pioneer of contactless health monitoring whose technology can take over 30 medical-grade health vitals using any video-enabled device, showcased its new Anura Telehealth platform at ViVE 2023. Leveraging sophisticated AI and proprietary optical technology, the telehealth platform performs continuous health and vital sign measurements while on a video call, making telehealth sessions more valuable for both patients and health professionals.
Founded in 2015, NuraLogix’s groundbreaking technology allows third-party clients such as health providers, insurance companies, and wellness programs to help consumers better manage their physical and mental health. At ViVE 2023, NuraLogix is showcasing the Anura platform with the ability to perform metabolic and blood biomarker health risk assessments for various chronic conditions, such as assessing HbA1c and fasting glucose and risk of type 2 diabetes, hypertension, and hypertriglyceridemia.
“Post-pandemic telemedicine has increasingly become the norm. While convenient and cost-effective, remote visits have until now lacked the ability for health professionals to carry out the routine health checks they would normally perform in the clinical setting,” said Dr. Keith Thompson, Chief Medical Officer at NuraLogix. “From heart rate to blood pressure, Anura Telehealth allows this to occur in real-time while also helping physicians to leverage the power of AI and its potential to help identify, predict and prevent chronic and acute diseases.”
Face The Future
Anura is the only video-based contactless health monitoring solution that can measure vital signs and provide health risk assessments. Unlike smartwatches, health trackers, and rings that track blood flow through light sensors, Anura can do so with a video selfie. You can see it in action here.
The entire Anura platform is powered by NuraLogix’s patented Transdermal Optical Imaging (TOI) technology, a novel form of Remote Photoplethysmography (rPPG). It automatically detects a person’s face, identifies key regions of interest, and extracts blood flow information that is combined with powerful AI data models developed from tens of thousands of patients with multiple health conditions.
Results are delivered within its intuitive app, showing measurement results for dozens of health parameters such as heart rate, breathing rate, and cuffless blood pressure, and providing health risk assessments for some of the most prevalent chronic conditions. This includes type 2 diabetes, hypertension, cardiovascular disease, and mental health.
Telehealth Sessions with real-time Health Data
Anura Telehealth is designed to enable true, two-way video telemedicine sessions and enhance remote patient monitoring, making these sessions more useful to both patients and healthcare professionals. The Anura Telehealth platform provides richer interaction between patients and healthcare professionals with the ability to provide real-time information and assist physicians in identifying future health risks. The solution is designed for use in the telehealth, remote patient management, and insurance industries. Key features of the platform include:
- Continuous real-time vital sign measurement during a video call
- Ability to integrate with 3rd party video conference platforms
- Compatible with telehealth solutions such as Doxy.me
- Customizable interfaces, templates, and reporting to accommodate different use cases
In addition, to measuring health vitals, Anura has the game-changing ability to carry out real-time health risk health assessments. Uniquely, Anura can assess HbA1c, monitor fasting glucose, and assess the risk of type 2 diabetes, hypertension, and hypertriglyceridemia. Its research models have currently appeared in 10 global peer-reviewed research publications, with three additional publications in progress covering topics of hypertension, multi-year cardiovascular risk, diabetes, and more. Its latest released models have been proven to predict whether a subject’s HbA1c is greater than 5.7% or their Fasting Blood Glucose is greater than 5.5mmol/L to a clinically accurate level.
A complete list of their research can be found here.
